Follow The Filings

COGT Cogent Biosciences Inc.

Health Care, filed as COGENT BIOSCIENCES INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • $658K

Who owns COGT

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management <0.01% Hold 17,000 $658K History

1 current, options excluded

Insider trades

Open-market buys and sales by COGT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All COGT insider trades
  • None no insider bought on the open market
  • $382M sold by 5 insiders outside a trading plan
  • $1.7M sold by 1 insider under 10b5-1 plans
  1. Arlene Morris Director
    Planned sale
    $1.7M 45,510 shares at $37.12 100% of stake
    Traded Aug 27 Filed Aug 31
    ↗
  2. Fairmount Funds Management LLC Director
    Sale
    $243M 7,000,000 shares at $34.66 56% of stake
    Traded Mar 31 Filed Mar 31
    ↗
  3. Fairmount Funds Management LLC Director
    Sale
    $127M 3,500,000 shares at $36.40 39% of stake
    Traded Jan 22 Filed Jan 22
    ↗
  4. Evan Kearns Chief Legal Officer
    Sale
    $2.5M 65,000 shares at $38.70 37% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
    ↗
  5. John L. Green CFO
    Sale
    $3M 77,000 shares at $38.68 37% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
    ↗
  6. Jessica Sachs Chief Medical Officer
    Sale
    $3.2M 82,642 shares at $38.70 38% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
    ↗
  7. John Edward Robinson Chief Scientific Officer
    Sale
    $3.5M 90,000 shares at $38.74 39% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 6 share withholdings for taxes, 2 gifts, 2 option exercises, and 1 conversion.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 1.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$192.41M -$255.86M -$328.94M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $270.77M $296.47M $910.36M
Total non-current assets * $42.67M $31.43M $27.25M
Total assets $313.44M $327.9M $937.61M
Total current liabilities $38.17M $55.71M $63.95M
Total non-current liabilities * $17.47M $15.9M $237.28M
Total equity $257.8M $256.29M $636.37M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$153.62M -$207.79M -$264.44M
Cash from investing -$97.82M $38.28M -$399.53M
Cash from financing $163.54M $214.45M $878.23M
Net change in cash -$87.91M $44.94M $214.26M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.